Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

Susvimo and VEGFxAng-2 bispecific antibody Vabysmo (faricimab) were intended to step into the breach and maintain Roche's franchise in eye disease. While Susvimo hit the buffers, Vabysmo has ...

Blockbuster Vabysmo has already been available in Europe ... recent approval in July this year when RVO was added to its EU label. Both the prefilled syringe and vials deliver faricimab, a ...

Approval of new drugs and label expansion of the existing ones should bode well for Roche. Drugs like Vabysmo, Ocrevus, ...

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the data for ...